(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 April 2013 (18.04.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/053873 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61K 31/5517* (2006.01)
C07D 519/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2012/070233

(22) International Filing Date:
12 October 2012 (12.10.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/547,198 14 October 2011 (14.10.2011) US

(71) Applicants: **SPIROGEN SÀRL** [CH/CH]; Chemin De La Pacottaz 1, c/o Michael Forer, CH-1806 St-Légier-La Chiésaz (CH). **SEATTLE GENETICS, INC.** [US/US]; 21823 30th Drive S.E., Bothell, Washington 98021 (US).

(72) Inventors: **HOWARD, Philip Wilson**; Spirogen Limited, The QMB Innovation Centre, 42 New Road, London Greater London E1 2AX (GB). **TIBERGHIEN, Arnaud**; Spirogen Limited, The QMB Innovation Centre, 42 New Road, London Greater London E1 2AX (GB). **JEFFREY, Scott**; Seattle Genetics, Inc., 21823 30th Drive S.E., Bothell, Washington 98021 (US). **BURKE, Patrick**; Seattle Genetics, Inc., 21823 30th Drive S.E., Bothell, Washington 98021 (US).

(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis LLP, 33 Gutter Lane, London Greater London EC2V 8AS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: PYRROLOBENZODIAZEPINES



(57) Abstract: A compound with the formula (I), wherein: R^2 is of formula (II), where X is selected from the group comprising: OH, SH, CO_2H, COH, N=C=O, $NHNH_2$, $CONHNH_2$, formula (A), formula (B), NHR^N, wherein R^N is selected from the group comprising H and C_{1-4} alkyl; R^{C1}, R^{C2} and R^{C3} are independently selected from H and unsubstituted C_{1-2} alkyl; and either: R^{12} is selected from the group consisting of: (ia) C_{5-10} aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C_{1-7} alkyl, C_{3-7} heterocyclyl and bis-oxy-C_{1-3} alkylene; (ib) C_{1-5} saturated aliphatic alkyl; (ic) C_{3-6} saturated cycloalkyl; (id) formula (C), wherein each of R^{21}, R^{22} and R^{23} are independently selected from H, C_{1-3} saturated alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl and cyclopropyl, where the total number of carbon atoms in the R^{12} group is no more than 5; (ie) formula (D), wherein one of R^{25a} and R^{25b} is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and (if) formula (E), where R^{24} is selected from: H; C_{1-3} saturated alkyl; C_{2-3} alkenyl; C_{2-3} alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2, NHR, NRR', nitro, Me_3Sn and halo; where R and R' are independently selected from optionally substituted C_{1-12} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups; R^7 is selected from H, R, OH, OR, SH, SR, NH_2, NHR, NHRR', nitro, Me_3Sn and halo; either: (a) R^{10} is H, and R^{11} is OH, OR^A, where R^A is C_{1-4} alkyl; (b) R^{10} and R^{11} form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R^{10} is H and R^{11} is SO_zM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R" is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms, and/or aromatic rings; Y and Y' are selected from O, S, or NH; $R^{6'}$, $R^{7'}$, $R^{9'}$ are selected from the same groups as R^6, R^7 and R^9 respectively and $R^{10'}$ and $R^{11'}$ are the same as R^{10} and R^{11}, wherein if R^{11} and $R^{11'}$ are SO_zM, M may represent a divalent pharmaceutically acceptable cation.

WO 2013/053873 A1